Dr René Kuijten joined LSP in 2001 and is Managing Partner and co-owner of the firm. René has founded and supported many life sciences companies as a supervisory board director, eleven of which have been acquired or have listed on international stock exchanges. His most recent exit was Neuravi (Ireland) working on stroke, sold to Johnson & Johnson. He is currently on the board of Simplify Medical (US/Australia) working on cervical discs, Artios Pharma (UK), active in the area of DNA repair and Alizé Pharma (France), focusing on rare diseases. As Managing Partner, René is also actively involved in the strategic planning, general management and fundraising of LSP; he was instrumental in raising the LSP 3 - 6 funds as well as HEF 1.
In addition, René initiated the Oncode Institute, uniting top cancer research and valorisation, where he is currently a supervisory board member. René was a board member of the Dutch Private Equity and Venture Capital Association (NVP) for 12 years, in which role he initiated the Dutch Venture Initiative (DVI), € 400 million government-backed fund-of-funds that invest in top-tier Dutch Venture firms. Furthermore René is amongst others a member of the national Topsector Life Sciences & Health (Health~Holland); chairman of the Emma Children’s Hospital charity; and treasurer of the board of the Vereniging Rembrandt.
Prior to joining LSP, René was a senior consultant for 8 years at McKinsey & Company in Amsterdam, Brussels and Zurich, where he was responsible for McKinsey’s European Healthcare Practice.
René studied at the University of Utrecht, Harvard Medical School and the Mayo Clinics for his Medical Doctor degree. He obtained his PhD at the University of Amsterdam on research performed at the University of Pennsylvania as a WHO fellow, and he authored several scientific articles including in The New England Journal of Medicine. René obtained an MBA from INSEAD in Fontainebleau, France. René lives in Baarn with his wife and four children.